NCT07071649View on ClinicalTrials.gov

Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Alzheimer's DiseaseBiomarkersNon-invasive DiagnosisPhosphorylated Protein p-tau217
Interventions
OTHER

blood withdrawal

blood withdrawal

Trial Locations (1)

80090

CHRU Amiens, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER